SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …
therapies in patients with type 2 diabetes mellitus and are associated with improved …
[HTML][HTML] Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease
A Chait, LJ Den Hartigh - Frontiers in cardiovascular medicine, 2020 - frontiersin.org
Adipose tissue plays essential roles in maintaining lipid and glucose homeostasis. To date
several types of adipose tissue have been identified, namely white, brown, and beige, that …
several types of adipose tissue have been identified, namely white, brown, and beige, that …
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes …
AJ Garber, Y Handelsman, G Grunberger, D Einhorn… - Endocrine Practice, 2020 - Elsevier
ABSTRACT Abbreviations: A1C= hemoglobin A1C; AACE= American Association of Clinical
Endocrinologists; ABCD= adiposity-based chronic disease; ACCORD= Action to Control …
Endocrinologists; ABCD= adiposity-based chronic disease; ACCORD= Action to Control …
[HTML][HTML] Carbohydrate-based drugs launched during 2000− 2021
X Cao, X Du, H Jiao, Q An, R Chen, P Fang… - … Pharmaceutica Sinica B, 2022 - Elsevier
Carbohydrates are fundamental molecules involved in nearly all aspects of lives, such as
being involved in formating the genetic and energy materials, supporting the structure of …
being involved in formating the genetic and energy materials, supporting the structure of …
Pharmacotherapy of type 2 diabetes: An update and future directions
A DeMarsilis, N Reddy, C Boutari, A Filippaios… - Metabolism, 2022 - Elsevier
Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …
social impact for which multiple conventional and novel pharmacotherapies are currently …
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study …
MJ Davies, DA D'Alessio, J Fradkin, WN Kernan… - Diabetes …, 2018 - pmc.ncbi.nlm.nih.gov
The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the prior position statements, published in 2012 and 2015, on …
convened a panel to update the prior position statements, published in 2012 and 2015, on …
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the …
MJ Davies, DA D'Alessio, J Fradkin, WN Kernan… - Diabetologia, 2018 - Springer
Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …
Diabetes convened a panel to update the prior position statements, published in 2012 and …
Left ventricular hypertrophy and hypertension
M Yildiz, AA Oktay, MH Stewart, RV Milani… - Progress in …, 2020 - Elsevier
Hypertension (HTN) is a major modifiable risk factor for cardiovascular disease (CVD)
morbidity and mortality. The left ventricle (LV) is a primary target for HTN end-organ damage …
morbidity and mortality. The left ventricle (LV) is a primary target for HTN end-organ damage …
Empagliflozin and progression of kidney disease in type 2 diabetes
Background Diabetes confers an increased risk of adverse cardiovascular and renal events.
In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 …
In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 …
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …